BIIB · Q3 2025 Earnings
CautiousBiogen
Reported October 14, 2025
30-second summary
Biogen raised FY2025 revenue growth guidance from "approximately flat" to "flat to +1%" at constant currency on continued launch-portfolio strength (Leqembi +82% YoY, Zurzuvae +150% YoY, Skyclarys +30% YoY). The updated FY non-GAAP EPS guide reflects +$0.25/share underlying improvement offset by an approximately $1.25/share Q4 BD charge — net ~$1.00/share lower than prior at the midpoint. Management's tone on the late-stage pipeline (10 Phase 3 programs) and BD pace remains the most confident it has been in over a year; the headline "stronger underlying business" framing is real, but reported EPS will land below where the prior guide implied.
Guidance
Company raised full-year revenue growth outlook to flat-to-+1% (from flat) but offset gains with ~$1.25/share business development charge in Q4, resulting in net non-GAAP EPS headwind despite 'stronger underlying business outlook.'
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| operating expenses | Q4 FY2025 | Approximately $1.1 billion | — |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Revenue growth (FY) | FY 2025 | Approximately flat at constant currency vs. FY2024 | Roughly flat to up 1% at constant currency vs. prior year | From flat to +0.5% midpoint (modest upside revision) | Raised |
| Non-GAAP EPS (FY) | FY 2025 | $15.50 to $16.00 | $15.50 to $16.00 (before ~$1.25/share business development charge) | Effective reduction of ~$1.25/share due to Q4 business development transactions; underlying guidance reaffirmed but net impact negative | Lowered |
Reaffirmed unchanged this quarter: Non-GAAP R&D and SG&A combined (Not explicitly re-stated in current guidance)
Management tone
Q4 FY2024 MS-cliff defense → Q1 FY2025 launches gaining → Q2 FY2025 launches lead, MS resilient → Q3 FY2025 launches at $1.2B TTM, pipeline as conviction story, early-stage BD as deliberate expansion
A year ago the early-stage pipeline read as a residual of R&D cost cuts. This quarter management framed it as deliberate strategic expansion, with BIB142 in Phase 1, Alcyon acquired, Anquibio C5A-R1 licensed, and explicit guidance for "another three to four molecules into our early stage pipeline over the coming 18 months" plus "at least another one, if not two, further research stage deals by the end of the year." The anchor quote: "I think as I look at the pipeline, I'd say we've got a very exciting and a high conviction late stage pipeline...we've got a stronger pipeline than we did before...we are very disciplined about where we put that cash flow." The shift signals management believes the late-stage pipeline is de-risked enough to redirect capital toward refilling the funnel — and the $1.25/share Q4 BD charge is the financial expression of that conviction.
Leqembi commentary has migrated across four quarters from "build infrastructure" (Q4 FY24) → "infrastructure maturing" (Q1) → "market is ready, going DTC" (Q2) → "market-leading and market-creating" this quarter. Alicia framed Leqembi as holding "majority share as the number one prescribed anti-amyloid treatment" and "the first and only anti-amyloid treatment to offer an at-home injection," with 82% YoY growth. The subtle but important shift: the franchise is no longer being defended against Kisunla; it is being positioned for category expansion via AHEAD 345 into pre-symptomatic populations. That requires confidence the current commercial position is durable.
The framing of Phase 3 trial recruitment as a commercial leading indicator is new and unusually bullish. Chris on litifilimab: "if we can accelerate, and we can accelerate in a competitive environment, that tells me that already physicians are seeing something special about litifilimab, and I'm certainly encouraged by that, not just from the fact that we're going to get the data earlier, but as I say, I think it's a good sign for the commercial success longer term of the product." Treating enrollment speed as a market-signal proxy is a meaningfully more confident posture — and it raises the cost of a miss if H2 2026 data disappoints.
The MS narrative has flipped from "resilient" (Q2) to "accelerating ex-U.S. erosion" (Q3). Management was explicit that Q4 Tecfidera erosion will be "roughly double" Q3. This is the one defensive tonal note in an otherwise forward-leaning quarter, and it does some of the work explaining why the revenue raise was only a midpoint nudge rather than a larger upgrade despite launch acceleration.
The Fit for Growth narrative continues to function as a discipline anchor. Reaffirming the $1B gross / $800M net savings target by end-2025 while simultaneously announcing the $1.25/share BD charge is the line management is drawing — capital discipline on the base, conviction-led investment on growth.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Umar Rafat · Evercore
How would positive Evoke Trial results impact Lakembi franchise and Biogen's portfolio strategy in Alzheimer's? Would Biogen need GLP-1 collaboration or in-house assets?
Management indicated Evoke Trial, if positive, would likely be used in primary care at earlier stages without directly affecting amyloid plaque. Emphasized Biogen's interest in a full portfolio of Alzheimer's products including BID-80 and brain shuttle technology. Highlighted that neuroinflammation hypothesis doesn't target pathology and that anti-amyloid antibodies were stable in trial patients. Noted the trial would increase disease awareness.
Evan Segerman · BMO Capital Markets
How will Biogen's focus on immunology drive growth and pipeline expansion through the end of the decade? What can Biden (presumably Biogen's internal initiatives) do to accelerate programs?
Management framed Biogen as historically an immunology company (MS treatment affects immune system). Near-term focus is rare immunology and areas with existing expertise (e.g., lupus leveraging MS experience). Longer-term 10-year strategy includes broader immunology indications. Emphasized deep scientific understanding of disease pathways and cross-over mechanisms (NRF2, microglia). Cited Vanqua as example of multi-indication asset acquisition. Reaffirmed continued strong investment in neuroscience (Alzheimer's, ALS, Parkinson's).
Salveen Richter · Goldman Sachs
What is management's confidence level in the late-stage pipeline (10 Phase III trials) that allows focus on early-stage pipeline expansion via BD?
Management expressed high confidence in late-stage pipeline based on Phase II data across multiple programs. Felzotamab: 80% AMR resolution and sustained IGAN benefit at 2 years post-treatment suggesting disease-modification. BID-80: pioneering tau reduction to unprecedented levels. Lupus: strong Phase II results, especially in CLE (no approved competitors); piralizumab already proven in one Phase III. Characterized pipeline transformation from 'moonshots' to 'thoughtful progression and de-risking.' Peak sales potential of late-stage pipeline substantial relative to existing business.
Answers to last quarter's watch list
What to watch into next quarter
Which BD assets close in Q4 and at what valuation. A $1.25/share charge implies ~$185M of accounting impact tied to the disclosed Anquibio license and Alcyon acquisition; the strategic read on whether this was money well spent depends on early pipeline progression.
Underlying FY2025 non-GAAP EPS ex-BD charge. Whether the +$0.25/share underlying improvement holds — and where reported FY EPS lands once the ~$1.25/share charge is absorbed — will determine whether the "stronger underlying business" framing was real.
Q4 ex-U.S. MS erosion magnitude. Management guided Q4 Tecfidera Europe erosion to be "roughly double" Q3's $28M sequential decline — the absolute dollar hit will determine whether the launch portfolio acceleration can carry the FY raise into reported numbers.
Leqembi U.S. in-market sales and China inventory drawdown completion. China Q4 capped by remaining 6-month inventory build; watch when normalized China contribution resumes and whether U.S. in-market sales sustain the +82% global growth trajectory.
Litifilimab H2 2026 readout positioning. Management has now framed recruitment speed as a commercial proxy; any commentary in Q4 on enrollment quality or interim data would be the next tell on whether the conviction is being validated or walked back.
Whether the 3–4 early-stage molecules and 1–2 research-stage deals materialize on the stated 18-month timeline. Management committed to a specific cadence; missing it would undermine the "deliberate pipeline expansion" narrative.
Sources
- Biogen Q3 FY2025 earnings press release (Form 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/875045/000087504525000040/R1.htm
- Biogen Q3 FY2025 earnings call transcript (prepared remarks and Q&A), October 14, 2025.
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.